Dose-Response Relationship of Ginger Flour Footbaths in Healthy Volunteers

Sponsor
ARCIM Institute Academic Research in Complementary and Integrative Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT04051476
Collaborator
University Hospital Tuebingen (Other)
16
1
4
4.5
3.6

Study Details

Study Description

Brief Summary

A study to explore whether different dosages of ginger flour in footbaths cause different effects on warmth development as well as on general well-being and the autonomic nervous system.

Condition or Disease Intervention/Treatment Phase
  • Other: 3-g footbath
  • Other: 6-g footbath
  • Other: 12-g footbath
  • Other: Warm water footbath
N/A

Detailed Description

This is a four-arm randomized controlled trial with crossover design to explore the dose-response relationship of footbaths with different dosages of ginger flour in healthy volunteers, compared to a placebo control (footbath with warm water only). The main focus is on thermogenesis and warmth distribution, as assessed by high-resolution infrared thermography and questionnaire data before, during and after the intervention. In addition, effects on the autonomic nervous system are assessed by measuring various parameters of heart rate variability and pulse wave analysis.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Dose-Response Relationship of Ginger Flour Footbaths in Healthy Volunteers - a Randomized, Controlled, Four-Arm Study With Crossover Design
Actual Study Start Date :
Sep 16, 2019
Actual Primary Completion Date :
Jan 30, 2020
Actual Study Completion Date :
Jan 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3-g footbath

Footbath with 3g ginger flour per liter of water

Other: 3-g footbath
A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.

Experimental: 6-g footbath

Footbath with 6g ginger flour per liter of water

Other: 6-g footbath
A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.

Experimental: 12-g footbath

Footbath with 12g ginger flour per liter of water

Other: 12-g footbath
A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.

Placebo Comparator: Warm water footbath

Footbath with warm water only

Other: Warm water footbath
A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.

Outcome Measures

Primary Outcome Measures

  1. 2-item warmth perception measure at the feet after the footbath [Immediately after the footbath, timepoint 2 (t2)]

    Self-reported warmth perception at both feet, assessed with the "Herdecke warmth perception questionnaire" immediately after the footbath (t2). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a mean between 0 and 4.

Secondary Outcome Measures

  1. 2-item warmth perception measure at the feet at t1 and t3 [Immediately before (t1) and 10 minutes following the footbath (t3)]

    Self-reported warmth perception at both feet, assessed with the "Herdecke warmth perception questionnaire" immediately before (t1) and 10 minutes following the footbath (t3). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a mean between 0 and 4.

  2. 2-item warmth perception measure at the hands at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3).]

    Self-reported warmth perception at both hands, assessed with the "Herdecke warmth perception questionnaire" immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a mean between 0 and 4.

  3. 2-item warmth perception measure at the head at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Self-reported warmth perception at the head, assessed with the "Herdecke warmth perception questionnaire" immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3). Each item is scored 0-4 (0 = cold; 4 = hot), yielding a mean between 0 and 4.

  4. 1-item overall warmth perception measure at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Self-reported overall warmth perception, assessed with the "Herdecke warmth perception questionnaire" immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3). The item is scored 0-4 (0 = cold; 4 = hot).

  5. Warmth perception and skin stimulus at the feet during the footbath [Up to 20 minutes]

    Self-reported perception of warmth and skin stimulus during the footbath, assessed with a dynamic warmth and skin stimulus visual analog scale (VAS), applied once per minute (0 = cold/no stimulus; 10 = very hot/very strong stimulus).

  6. Well-being at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Self-reported well-being, assessed with the "Basler Befindlichkeits-Skala" (Basel Mood Questionnaire, BBS) immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3). (BBS: 16 items; 7-point rating scale; higher values represent a better outcome.)

  7. Skin surface temperature at the feet at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Skin surface temperature (°C) at both feet, measured with high-resolution infrared thermography immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3).

  8. Skin surface temperature at the lower legs at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Skin surface temperature (°C) at both lower legs, measured with high-resolution infrared thermography immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3).

  9. Skin surface temperature at the hands at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Skin surface temperature (°C) at both hands, measured with high-resolution infrared thermography immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3).

  10. Skin surface temperature in the face at t1, t2 and t3 [Immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3)]

    Skin surface temperature (°C) in the face, measured with high-resolution infrared thermography immediately before (t1), immediately after (t2) and 10 minutes following the footbath (t3).

  11. HRV analysis: HF [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    High frequency power band (0.15-0.40 Hz) (ms2) from frequency domain analysis, obtained from ECG recordings throughout the intervention and the pre- and post-intervention rest periods (VitaGuard® 3100 monitor, getemed, Germany).

  12. HRV analysis: LF [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Low frequency power band (0.04-0.15 Hz) (ms2) from frequency domain analysis (VitaGuard® 3100 monitor, getemed, Germany).

  13. HRV analysis: LF/HF ratio [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    LF/HF ratio = ratio of two bands from frequency domain analysis: LF band (0.04-0.15 Hz), HF band (0.15-0.40 Hz) (VitaGuard® 3100 monitor, getemed, Germany).

  14. HRV analysis: SDNN [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Standard deviation of normal to normal (NN) intervals (ms) (VitaGuard® 3100 monitor, getemed, Germany).

  15. HRV analysis: RMSSD [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Root mean square of successive differences (ms) (VitaGuard® 3100 monitor, getemed, Germany).

  16. HRV analysis: pNN50 [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Percentage of successive NN intervals that differ from each other by more than 50 ms (%) (VitaGuard® 3100 monitor, getemed, Germany).

  17. Pulse wave analysis: Pulse Transit Time [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Pulse Transit Time (PTT, ms), obtained from pulse oximetry recordings throughout the intervention and the pre- and post-intervention rest periods (VitaGuard® 3100 monitor, getemed, Germany).

  18. Pulse wave analysis: Reflection Index [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Reflection Index (RI, %), obtained from pulse oximetry recordings throughout the intervention and the pre- and post-intervention rest periods (VitaGuard® 3100 monitor, getemed, Germany).

  19. Pulse wave analysis: Perfusion Index [Up to 40 minutes (continuous measurement from the beginning of the pre-intervention rest period to the end of the post-intervention rest-period)]

    Perfusion Index (PI, %), obtained from pulse oximetry recordings throughout the intervention and the pre- and post-intervention rest periods (VitaGuard® 3100 monitor, getemed, Germany).

  20. Evening morning protocol: perception of warmth and stimulus at the feet [On the evening of the footbath, before going to sleep; on the following morning, within 15 minutes after waking up]

    Self-reported lasting effects of the footbaths at the feet, indicated on a seven-point rating scale (higher values represent a better outcome)

  21. Evening morning protocol: skin condition [On the evening of the footbath, before going to sleep; on the following morning, within 15 minutes after waking up]

    Self-reported lasting effects of the footbaths on skin condition, indicated on a seven-point rating scale (higher values represent a better outcome)

  22. Evening morning protocol: general well-being [On the evening of the footbath, before going to sleep; on the following morning, within 15 minutes after waking up]

    Self-reported lasting effects of the footbaths on general well-being, indicated on a seven-point rating scale (higher values represent a better outcome)

  23. Morning protocol: sleep quality [In the morning after the footbath, within 15 minutes after waking up]

    Self-reported sleep quality during the night following the footbaths, indicated on a seven-point rating scale (higher values represent a better outcome)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Written informed consent

  • Age between 18 and 55 years

Exclusion Criteria:
  • Chronic skin lesions at the lower legs or feet

  • Known intolerance or hypersensitivity to ginger preparations

  • Cardiac arrhythmia

  • Cardiac pacemaker

  • Asthma bronchiale

  • Consumption of HRV-modulating medication (especially tricyclic antidepressants, beta blockers)

  • Pregnancy

  • Insufficient knowledge of the german language

Contacts and Locations

Locations

Site City State Country Postal Code
1 Arcim Institute Filderstadt Baden-Württemberg Germany 70794

Sponsors and Collaborators

  • ARCIM Institute Academic Research in Complementary and Integrative Medicine
  • University Hospital Tuebingen

Investigators

  • Principal Investigator: Jan Vagedes, Dr., Arcim Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ARCIM Institute Academic Research in Complementary and Integrative Medicine
ClinicalTrials.gov Identifier:
NCT04051476
Other Study ID Numbers:
  • SWI_08
First Posted:
Aug 9, 2019
Last Update Posted:
Apr 28, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ARCIM Institute Academic Research in Complementary and Integrative Medicine

Study Results

No Results Posted as of Apr 28, 2020